The EMPACT-MI trial investigated the effects of empagliflozin treatment soon after an acute MI on heart failure (HF) hospitalization or death from any cause. While the primary endpoint was not met, the study found a reduction in certain HF-related outcomes with empagliflozin. Patients receiving empagliflozin had a lower risk of HF hospitalization compared to placebo. The safety profile of empagliflozin was consistent with known effects. Overall, the results suggest a benefit of empagliflozin in reducing HF risk post-acute MI, highlighting the potential role of SGLT2 inhibitors in this patient population.
Source link
Empagliflozin did not cut risk for death, HF hospitalization after heart attack: EMPACT-MI
